Research Associate I/II, Stem Cell Biology and Differentiation
BlueRock Therapeutics
Summary
The New York, USA site is seeking a Research Associate I or II for the Platform Bioprocess pipeline that will be reporting to the sub-team lead.
Job description
The incumbent will be a technical contributor in a dynamic and progressive team pioneering the generation of therapeutic cells from human pluripotent stem cells (hPSCs). Within an exciting collaborative environment, the individual is expected to learn and apply their knowledge of human pluripotent stem cell biology and lineage-directed differentiation techniques to help generate cell lines and bioprocess supply for BlueRock's research pipeline. This may include assisting in the generation and performing the directed differentiation of hPSC lines engineered with gene editing technologies including CRISPR/Cas to determine whether genome alterations provide BlueRock authentic cell types with novel morphology or function for cellular replacement therapies.
Responsibilities
- Execute in vitro experiments to characterize and cultivate hPSCs and their derivatives.
- Perform DNA/RNA-based, cell-based, flow cytometric, immunofluorescence and other protein-based analytical assays as required.
- Perform directed differentiation of hPSCs into various cell lineages.
- Coordinate and interact with other functional areas to complete characterization of generated cell lines and their derivative products.
- Analyze and document experimental data in electronic laboratory notebooks in a timely and accurate manner in accordance with the company quality management system.
- Be responsible for data generation, collection and communication of results.
- Prepare and follow standard operating procedures, batch records and other process documentation.
- Attend and present scientific data to colleagues at internal meetings.
Minimum Requirements
- B.S. or M.Sc. in cell biology, developmental biology, molecular biology, genetics or related discipline, with up to 5 years (if B.S.) or 3 years (if M.Sc.) laboratory research or industry experience.
- Experience with human pluripotent stem cell or mammalian cell culture.
- Experience with lineage-specific differentiation of human pluripotent stem cells is preferred.
- Experience with cell characterization technologies including PCR, DNA sequencing, qPCR, flow cytometry and immunofluorescence.
- Experience with molecular cloning and gene editing technologies is a plus.
- Excellent analytical, problem solving and organizational skills.
- Strong written and verbal communications skills.
Requirements
- B.S. or M.Sc. in cell biology, developmental biology, molecular biology, genetics or related discipline
- Up to 5 years laboratory research or industry experience (B.S.) or 3 years (M.Sc.)
- Experience with human pluripotent stem cell or mammalian cell culture
- Experience with cell characterization technologies including PCR, DNA sequencing, qPCR, flow cytometry and immunofluorescence
- Excellent analytical, problem solving and organizational skills
- Strong written and verbal communications skills
Company overview
BlueRock Therapeutics is a clinical-stage biotechnology company pioneering engineered cell therapies for the treatment of devastating neurological and ophthalmic diseases. Founded in 2016 as a joint venture between Versant Ventures and Leaps by Bayer, the company became a wholly owned, independently operated subsidiary of Bayer AG in late 2019. BlueRock leverages its proprietary induced pluripotent stem cell (iPSC) platform to develop novel cellular medicines that aim to transform disease treatment through regenerative approaches. The company's pipeline includes two clinical-stage programs: bemdaneprocel (BRT-DA01) for Parkinson's disease and OpCT-001 for primary photoreceptor diseases affecting vision. With operations spanning Cambridge, Massachusetts; Toronto, Ontario; New York; and Berlin, BlueRock employs 201-500 professionals dedicated to advancing cell and gene therapies. The company's mission centers on harnessing the power of cell therapy to create breakthrough medicines for patients with limited treatment options, operating at the intersection of neurology, cardiology, and immunology research.